Standing Order
Recursion Pharmaceuticals, Inc.

Dashboard

Recursion Pharmaceuticals, Inc.

RXRXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$1.6B
Price$2.9652w $2.84 – $6.79
Conviction3/ 5
Revenue (TTM)$66M
Revenue growth YoY+11.0%
P/E (trailing)—
Gross margin-34.4%
Operating margin-882.9%
Net margin-844.5%
52w price change-32.3%
Next earningsAug 4, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Jul 9
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 2
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jul 2
    Ownership changeSEC

    Form 4 insider transaction filing by RXRX.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 22
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing for RXRX.

  • Jun 22
    Ownership changeSEC

    Form 4 insider transaction filing for RXRX.

  • Jun 18
    OtherSEC

    8-K filed disclosing results of matters submitted to shareholder vote (item 5.07).

  • Jun 17
    Ownership changeSEC

    SEC Form 4 insider transaction filing

  • Jun 11
    Trial initiationClinicalTrials.gov

    Recursion subsidiary Exscientia initiates Phase 1 dose-finding trial of EXS73565 in relapsed/refractory B-cell malignancies (NCT06980116, recruiting).

  • Jun 10
    Trial initiationClinicalTrials.gov

    Recursion subsidiary Exscientia initiates Phase 1 dose-finding trial of REC-4539 in select solid tumors (NCT07517198, recruiting)

  • Jun 5
    Trial initiationClinicalTrials.gov

    Phase 1/2 trial (NCT05552755) of REC-4881 in FAP updated to recruiting status

  • Jun 5
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jun 5
    Ownership changeSEC

    SEC Form 4 insider transaction filing

  • Jun 4
    Ownership changeSEC

    Form 4 insider transaction filing for RXRX

  • Jun 4
    Ownership changeSEC

    Form 4 insider transaction filing

  • May 27
    OtherSEC

    Form 4 insider transaction filing by RXRX executive or director.

Not financial advice — research and opinion only. Disclosures